Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Decheng Capital China Life Sciences USD Fund III, L.P., along with related entities, reported selling shares of BeyondSpring Inc. (NASDAQ:BYSI) between September 25 and September 29, 2025. The sales, executed in three separate transactions, totaled $3,045 with prices ranging from $1.66 to $1.75. The micro-cap biotech company, currently valued at $69 million, has shown mixed signals according to InvestingPro data, maintaining strong liquidity with a current ratio of 2.19 despite rapid cash burn.
On September 25, 700 shares were sold at prices ranging from $1.64 to $1.67. Followed by 600 shares sold on September 26, at prices between $1.65 and $1.73. The final transaction occurred on September 29, with 500 shares sold in the range of $1.72 to $1.76.
Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. directly holds 1,845,761 shares.
Decheng Capital China Life Sciences USD Fund II, L.P. holds 1,617,409 shares, and Decheng Capital Global Healthcare Fund (Master), LP holds 891,734 shares in BeyondSpring.
In other recent news, BeyondSpring Inc . has reported positive results from a clinical study involving its lead drug, Plinabulin. The study, published in Med (Cell Press), highlighted the efficacy of Plinabulin when combined with radiation and checkpoint inhibitors in patients who had previously not responded to immune checkpoint inhibitor (ICI) therapy. The Phase 1 translational trial demonstrated a 23% objective response rate and a 54% disease control rate in non-irradiated lesions among evaluable ICI-relapsed patients with eight different cancer types. Additionally, BeyondSpring has scheduled its 2025 annual meeting of shareholders for September 15, 2025. The record date for this meeting is set for the close of business on July 25, 2025. Shareholder proposals for inclusion in the proxy statement must be submitted by July 14, 2025, in accordance with Rule 14a-8 of the Securities Exchange Act. These developments mark significant steps for BeyondSpring in both its clinical and corporate agendas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.